Evolution of the Average Target: Structure Therapeutics Inc.

Evolution of the Target Price: Structure Therapeutics Inc.

Changes in Analyst Recommendations: Structure Therapeutics Inc.

34705d34b6ac6.zJY0sTEI1ZaaoAIHwKvGG0iXCuOjR8C5xBUmj41f2_M.tPMB10VZraDO0TdNqNL3TAnZQ63kH5mIh1Rnyu4p7Z3-xUTXRGu-7_H1YQ~6c207230f10835e62744e4a3606892e3
04-27 Canaccord Genuity Initiates Coverage on Structure Therapeutics With Buy Rating, $101 Price Target MT
25-08-06 Assembly Biosciences Q2 revenue rises from Gilead collaboration RE
25-05-02 Citigroup Initiates Coverage on Structure Therapeutics With Buy Rating, $60 Price Target MT
25-02-28 William Blair Initiates Structure Therapeutics at Outperform MT
24-12-04 HC Wainwright Initiates Structure Therapeutics at Buy MT
24-09-23 Structure Therapeutics Shares Rise After Morgan Stanley Begins Coverage at Overweight MT
24-09-23 Morgan Stanley Initiates Structure Therapeutics at Overweight MT
24-06-07 BMO Capital Adjusts Price Target on Structure Therapeutics to $100 From $83, Maintains Outperform Rating MT
24-05-21 JPMorgan Starts Structure Therapeutics With Overweight Rating MT
24-04-09 Cantor Fitzgerald Initiates Structure Therapeutics at Overweight Rating With $65 Price Target MT
23-11-15 JMP Securities Adjusts Structure Therapeutics' Price Target to $91 From $90, Keeps Market Outperform Rating MT
23-10-27 Piper Sandler Raises Price Target on Structure Therapeutics to $93 From $58, Maintains Overweight Rating MT
23-10-19 JMP Securities Starts Coverage on Structure Therapeutics with Market Outperform Rating, $90 Price Target MT
23-10-03 BMO Capital Adjusts Structure Therapeutics Price Target to $83 From $40, Maintains Outperform Rating MT
23-07-27 Piper Sandler Initiates Structure Therapeutics With Overweight Rating, $58 Price Target MT
23-02-28 SVB Securities Initiates Structure Therapeutics at Outperform Rating With $33 Price Target MT
23-02-28 BMO Capital Initiates Structure Therapeutics at Outperform With $40 Price Target MT
23-02-28 Jefferies Initiates Structure Therapeutics at Buy With $34 Price Target MT
23-02-28 Guggenheim Starts Structure Therapeutics at Buy With $50 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+122.29%
+19.12%
+11.09%
+64.75%
+18.05%
+13.05%
+6.66%
+26.26%
-5.63%
+25.87%
Average +30.15%
Weighted average by Cap. +21.08%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
47.13USD
Average target price
104.77USD
Spread / Average Target
+122.29%
High Price Target
145.00USD
Spread / Highest target
+207.66%
Low Price Target
69.50USD
Spread / Lowest Target
+47.46%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
  1. Stock Market
  2. Stocks
  3. GPCR Stock
  4. Consensus Structure Therapeutics Inc.